PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Discov
Glavni autori: Pantelidou, Constantia, Sonzogni, Olmo, De Oliveria Taveira, Mateus, Mehta, Anita K., Kothari, Aditi, Wang, Dan, Visal, Tanvi, Li, Michelle K., Pinto, Jocelin, Castrillon, Jessica A., Cheney, Emily M., Bouwman, Peter, Jonkers, Jos, Rottenberg, Sven, Guerriero, Jennifer L., Wulf, Gerburg M., Shapiro, Geoffrey I.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548644/
https://ncbi.nlm.nih.gov/pubmed/31015319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-1218
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items